APLLTD Alembic Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
Alembic Pharma reported a strong Q3 FY26, with revenue growing 11% year-over-year to INR 1,876 crores and PAT before exceptional items increasing 21% to INR 168 crores. Growth was broad-based across geographies, with ROW markets showing significant traction. While gross margins saw some moderation due to product mix and pricing pressures, operating leverage improved EBITDA. The company is on track for its first US branded product launch and continues to invest heavily in R&D and new product development.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 16.8%, net profit up 32.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 1,580 | 1,406 | 1,571 | 1,494 | 1,796 +14% | 1,642 +17% |
| EBITDA | 259 | 180 | 171 | 214 | 303 +17% | 272 +51% |
| Net profit | 166 | 86 | 75 | 104 | 179 +8% | 114 +33% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
